Lead Product(s) : Ibrilatazar,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : CTI Life Sciences
Deal Size : $7.6 million
Deal Type : Financing
AbilityPharma Raises €7M to Advance Phase 2b ABTL0812 for Metastatic Pancreatic Cancer
Details : AbilityPharma to obtain financing for the clinical development of ABTL0812 in combination with folfirinox. It is being evaluated in Phase I/II clinical trial studies for Metastatic Pancreatic Cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 03, 2024
Lead Product(s) : Ibrilatazar,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : CTI Life Sciences
Deal Size : $7.6 million
Deal Type : Financing
Lead Product(s) : Ibrilatazar
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 16, 2020
Lead Product(s) : Ibrilatazar
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibrilatazar
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Cleveland Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ABTL0812 in Pancreatic Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2018
Lead Product(s) : Ibrilatazar
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Cleveland Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibrilatazar
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Hospital Vall d'Hebron | Institut Català d'Oncologia | Hospital Clínico Universitario de Valencia | Hospitales Universitarios Virgen del Rocío | Centre Léon Bérard | Institut Paoli-Calmettes | Gustave Roussy
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Efficacy and Safety of ABTL0812
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 08, 2017
Lead Product(s) : Ibrilatazar
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Hospital Vall d'Hebron | Institut Català d'Oncologia | Hospital Clínico Universitario de Valencia | Hospitales Universitarios Virgen del Rocío | Centre Léon Bérard | Institut Paoli-Calmettes | Gustave Roussy
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibrilatazar
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Hospital Clinic of Barcelona | Institut Català d'Oncologia
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I/Ib Clinical Trial of ABTL0812 in Advanced Cancer Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2014
Lead Product(s) : Ibrilatazar
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Hospital Clinic of Barcelona | Institut Català d'Oncologia
Deal Size : Inapplicable
Deal Type : Inapplicable